Secondary hormonal therapy in men with castration-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 9, Issue 2, 2011, Pages 95-103

  Nakabayashi, Mari ^a   Werner, Lillian ^b   Oh, William K ^c   Regan, Meredith M ^b   Kantoff, Philip W ^a   Taplin, Mary Ellen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen deprivation therapy; Androgen resistance; Castration resistant prostate cancer; Natural history; Secondary hormonal therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; BICALUTAMIDE; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; HYDROXYFLUTAMIDE; KETOCONAZOLE; NILUTAMIDE; PC SPES; STEROID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES;

EID: 80055059101     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.06.006     Document Type: Article

References (41)

1. C. Huggins, and C.V. Hodges Studies in prostate cancer I. The effect of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Research 1 1941 243
2. M.E. Taplin, G.J. Bubley, and Y.J. Ko Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res 59 1999 2511 2515 (Pubitemid 29269089)
3. M.E. Taplin, G.J. Bubley, and T.D. Shuster Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
4. M.E. Taplin, B. Rajeshkumar, and S. Halabi Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663 J Clin Oncol 21 2003 2673 2678 (Pubitemid 46606310)
5. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 2001 34 45 (Pubitemid 33741879)
6. M. Stanbrough, G.J. Bubley, and K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
7. L.N. Thomas, R.C. Douglas, and C.B. Lazier Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer Eur Urol 53 2008 244 252 (Pubitemid 350296595)
8. B.Y. Bao, B.F. Chuang, and Q. Wang Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes Prostate 68 2008 839 848 (Pubitemid 351845215)
9. Z. Culig, A. Hobisch, and M.V. Cronauer Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone Mol Endocrinol 7 1993 1541 1550 (Pubitemid 24034236)
10. J.L. Mohler, C.W. Gregory, and O.H. Ford 3rd The androgen axis in recurrent prostate cancer Clin Cancer Res 10 2004 440 448 (Pubitemid 38173980)
11. M. Nakabayashi, W. Xie, and M.M. Regan Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer Cancer 107 2006 975 981 (Pubitemid 44291146)
12. M. Nakabayashi, M.M. Regan, and D. Lifsey Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer BJU Int 96 2005 783 786 (Pubitemid 41391380)
13. W.K. Oh, J. Hayes, and C. Evan Development of an integrated prostate cancer research information system Clin Genitourin Cancer 5 2006 61 66
14. H. Miyake, I. Hara, and H. Eto Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer BJU Int 96 2005 791 795 (Pubitemid 41391382)
15. E.J. Small, S. Halabi, and N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025 1033 (Pubitemid 41095034)
16. W. Kassouf, S. Tanguay, and A.G. Aprikian Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails J Urol 169 2003 1742 1744 (Pubitemid 36443485)
17. O. Kucuk, E. Fisher, and C.M. Moinpour Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235) Urology 58 2001 53 58 (Pubitemid 32633935)
18. R. Joyce, M.A. Fenton, and P. Rode High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy J Urol 159 1998 149 153 (Pubitemid 27525592)
19. H.I. Scher, C. Liebertz, and W.K. Kelly Bicalutamide for advanced prostate cancer: the natural versus treated history of disease J Clin Oncol 15 1997 2928 2938 (Pubitemid 27330021)
20. M. Pomerantz, J. Manola, and M.E. Taplin Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer J Urol 177 2007 2146 2150 (Pubitemid 46726391)
21. M.E. Taplin, M.M. Regan, and Y.J. Ko Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer Clin Cancer Res 15 2009 7099 7105
22. J.S. De Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
23. M.J. Shulman, and E.A. Benaim The natural history of androgen independent prostate cancer J Urol 172 2004 141 145 (Pubitemid 41615056)
24. M.R. Smith, F. Kabbinavar, and F. Saad Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925 (Pubitemid 46224110)
25. L.J. Emrich, R.L. Priore, and G.P. Murphy Prognostic factors in patients with advanced stage prostate cancer Cancer Res 45 1985 5173 5179 (Pubitemid 16236210)
26. W.R. Berry, J. Laszlo, and E. Cox Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate Cancer 44 1979 763 775 (Pubitemid 10233792)
27. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237 (Pubitemid 46606398)
28. O. Smaletz, H.I. Scher, and E.J. Small Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 2002 3972 3982
29. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506 2513 (Pubitemid 29368252)
30. R.W. Ross, W. Xie, and M.M. Regan Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect Cancer 112 2008 1247 1253 (Pubitemid 351429739)
31. M.E. Taplin Drug insight: role of the androgen receptor in the development and progression of prostate cancer Nat Clin Pract Oncol 4 2007 236 244
32. R.W. Ross, W.K. Oh, and W. Xie Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer J Clin Oncol 26 2008 842 847 (Pubitemid 351398074)
33. M. Nakabayashi, W.K. Oh, and S. Jacobus Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer BJU Int 105 2010 1392 1396
34. E.M. Van Allen, and C.J. Ryan Novel secondary hormonal therapy in advanced prostate cancer: an update Curr Opin Urol 19 2009 315 321
35. M.E. Taplin, J. Manola, and W.K. Oh A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones BJU Int 101 2008 1084 1089 (Pubitemid 351502663)
36. Y. Chen, N.J. Clegg, and H.I. Scher Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol 10 2009 981 991
37. G. Attard, A.H. Reid, and R. A'Hern Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
38. T. Vasaitis, A. Belosay, and A. Schayowitz Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Mol Cancer Ther 7 2008 2348 2357
39. R. Dreicer, D.B. Agus, and G.R. MacVicar Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study Genitourinary Cancers Symposium Proceedings 2010 Abstr 103
40. D.C. Danila, D.E. Rathkopf, and M.J. Morris Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy ASCO Annual Meeting 26 2008 Abstr 5019
41. O. Sartor, M. Nakabayashi, and M.E. Taplin Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone Clin Genitourin Cancer 7 2009 E90-2